Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

#665

Introduction: Surgery is the only potential for cure in patients with pancreatic neuroendocrine tumors (pNETs).

Aim(s): To describe the neoadjuvant use of [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) in nonfunctioning pNETs.

Materials and methods: We studied 119 Dutch patients with a nonfunctioning pNET treated with 177Lu-octreotate. Patients were divided into three groups: locally advanced tumor (group 1); ≤3 liver metastases (group 2); >3 liver metastases/other distant metastases (group 3). Patients in group 1+2 were considered neoadjuvant treated patients.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Van Vliet E, Van Eijck C, De Krijger R, Nieveen van Dijkum E, Teunissen J,

Keywords: pancreatic net, PRRT, neoadjuvant treatment, survival,